Literature DB >> 8385528

Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.

G Olmos1, A M Gabilondo, A Miralles, P V Escriba, J A García-Sevilla.   

Abstract

1. The binding of [3H]-idazoxan in the presence of 10(-6) M (-)-adrenaline was used to quantitate non-adrenoceptor idazoxan binding sites (NAIBS) in the rat brain after treatment with various psychotropic drugs. 2. Chronic treatment (14 days) with the monoamine oxidase (MAO) inhibitors clorgyline (0.3-10 mg kg-1, i.p.) and pargyline (10 mg kg-1, i.p.), but not with Ro 41-1049 (1 mg kg-1, i.p.), markedly decreased (30-50%) the density of NAIBS in the cerebral cortex without any apparent change in the affinity of the radioligand. 3. Acute (1 day) and/or chronic treatments (14 days) with other psychotropic drugs such as desipramine (3 mg kg-1, i.p.), cocaine (10 mg kg-1, i.p.), reserpine (0.12 mg kg-1, s.c.), haloperidol (1 mg kg-1, i.p.) and diazepam (10 mg kg-1, i.p.) did not alter the density of NAIBS in the cerebral cortex. 4. In vitro, the propargylamines clorgyline, pargyline and deprenyl displaced the binding of [3H]-idazoxan to NAIBS from two distinct sites, but only clorgyline displayed an apparent very high affinity for a relevant population of NAIBS (KiH = 40 pM; KiL = 10.6 microM). The structurally diverse MAO inhibitors Ro 16-6491 (selective for MAO-B) and Ro 41-1049 (selective for MAO-A), as well as the other psychotropic drugs (desipramine, cocaine, reserpine and haloperidol) displaced the binding of [3H]-idazoxan to NAIBS monophasically and with very low potencies. As expected, the MAO inhibitors clorgyline and Ro 41-1049 displaced the binding of [3H]-Ro 41-1049 to MAO-A monophasically and with high potencies (Ki values: 0.18 nM and 22 nM, respectively). In contrast, idazoxan displayed very low affinity (Ki =40 microM) against the binding of pH]-Ro 41-1049 to MAO-A. These results disprove a direct interaction between [3H]-idazoxan and the enzyme MAO.5. Preincubation of cortical membranes with clorgyline (10-9M or 10-6 M for 30 min) or pargyline(10-6 M or 10-5M for 30 min), reduced by 30-50% and by 17-30%, respectively, the total density of NAIBS without any apparent change in the affinity of the radioligand. Preincubation with 10-6M clorgyline did not alter the affinity of cirazoline for the two populations of NAIBS, but reduced by 60%the binding of [3H]-idazoxan to the high affinity site without affecting the binding of the radioligand to the low affinity site. These results indicate that the two MAO inhibitors irreversibly block the binding of[3H]-idazoxan to NAIBS.6. In vivo, however, various acute treatments with clorgyline (1-20 mg kg-1, i.p.) for different time intervals (6-48 h) did not alter the density of NAIBS. In vivo, only very high doses of clorgyline (40 and 80 mg kg-1, i.p.) induced modest decreases (21-28%) in the density of NAIBS in the cerebral cortex.7. Together the results indicate that the irreversible binding of clorgyline and pargyline to NAIBSfound in vitro does not fully explain the marked decreases in the density of NAIBS found in vivo after the chronic treatments. It is suggested that the down-regulation of NAIBS induced in vivo by clorgyline and pargyline, through a direct or indirect mechanism, may have functional implications.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8385528      PMCID: PMC1908014          DOI: 10.1111/j.1476-5381.1993.tb12848.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  A proposal for the classification of sigma binding sites.

Authors:  R Quirion; W D Bowen; Y Itzhak; J L Junien; J M Musacchio; R B Rothman; T P Su; S W Tam; D P Taylor
Journal:  Trends Pharmacol Sci       Date:  1992-03       Impact factor: 14.819

2.  Characterization of [3H]Ro 16-6491 binding to digitonin solubilized monoamine oxidase-B and purification of the enzyme from human platelets by affinity chromatography.

Authors:  A M Cesura; R Imhof; D Muggli-Maniglio; G B Picotti; M Da Prada
Journal:  Biochem Pharmacol       Date:  1990-01-01       Impact factor: 5.858

3.  Clorgyline displays high affinity for sigma binding sites in C57BL/6 mouse brain.

Authors:  Y Itzhak; C O Kassim
Journal:  Eur J Pharmacol       Date:  1990-01-25       Impact factor: 4.432

Review 4.  Are there multiple imidazoline binding sites?

Authors:  M C Michel; P A Insel
Journal:  Trends Pharmacol Sci       Date:  1989-09       Impact factor: 14.819

5.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC.

Authors:  G A McPherson
Journal:  J Pharmacol Methods       Date:  1985-11

Review 6.  The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.

Authors:  C J Fowler; L Oreland; B A Callingham
Journal:  J Pharm Pharmacol       Date:  1981-06       Impact factor: 3.765

7.  Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain.

Authors:  C L Boyajian; S E Loughlin; F M Leslie
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

8.  Acute and long-term regulation of brain alpha 2-adrenoceptors after manipulation of noradrenergic transmission in the rat.

Authors:  M T Giralt; J A García-Sevilla
Journal:  Eur J Pharmacol       Date:  1989-05-30       Impact factor: 4.432

9.  Differential regulation of sigma and PCP receptors after chronic administration of haloperidol and phencyclidine in mice.

Authors:  Y Itzhak; S Alerhand
Journal:  FASEB J       Date:  1989-05       Impact factor: 5.191

10.  [3H]Ro 16-6491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes.

Authors:  A M Cesura; R Imhof; B Takacs; M D Galva; G B Picotti; M Da Prada
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

View more
  15 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Differential effects of clorgyline on sensitization to quinpirole in rats tested in small and large environments.

Authors:  Anna Dvorkin; Kirsten E Culver; Henry Szechtman
Journal:  Psychopharmacology (Berl)       Date:  2006-05-11       Impact factor: 4.530

3.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

4.  Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors.

Authors:  P Sánchez-Blázquez; M A Boronat; G Olmos; J A García-Sevilla; J Garzón
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Pharmacological modulation of immunoreactive imidazoline receptor proteins in rat brain: relationship with non-adrenoceptor [3H]-idazoxan binding sites.

Authors:  P V Escribá; R Alemany; M Sastre; G Olmos; A Ozaita; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Pharmacological and molecular discrimination of brain I2-imidazoline receptor subtypes.

Authors:  G Olmos; R Alemany; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-12       Impact factor: 3.000

7.  Contrasting effects of the imidazol(in)e alpha 2-adrenoceptor agonists, medetomidine, clonidine and UK 14,304 on extraneuronal levels of noradrenaline in the rat frontal cortex: evaluation using in vivo microdialysis and synaptosomal uptake studies.

Authors:  J W Dalley; S C Stanford
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands.

Authors:  Andrew Holt; Barbara Wieland; Glen B Baker
Journal:  Br J Pharmacol       Date:  2004-09-27       Impact factor: 8.739

9.  [3H]-RS-45041-190: a selective high-affinity radioligand for I2 imidazoline receptors.

Authors:  A C MacKinnon; W S Redfern; C M Brown
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

10.  RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors.

Authors:  C M Brown; A C MacKinnon; W S Redfern; A Williams; C Linton; M Stewart; R U Clague; R Clark; M Spedding
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.